LSI USA

As technologies evolve and  healthcare innovation  accelerates, the traditional boundaries separating medtech, big tech, and big pharma are increasingly blurry — but the cultural and strategic gaps between them remain. At LSI USA ’25, panelists Juan-Pablo Mas (Action Potential Venture Capital), Nishant Doctor (Surf Therapeutics), and Jordi Parramon (Nexus NeuroTech Ventures) joined moderator Katie Elias to examine how medtech can better align with  big tech and big pharma  to drive innovation forward. The conversation centered on key differences in development strategy, investor expectations, and business timelines — critical challenges that arise when building partnerships or raising capital across sectors. As medtech companies seek broader platforms and more ambitious outcomes, understanding and navigating these differences becomes essential for effective cross-sector collaboration and long-term success. Understanding the Evidence Gap A major area of divergence bet...

For years, medical robotics has been synonymous with high-cost, high-precision interventions — think large surgical robots in complex operating rooms. But a new generation of robotics companies is upending that paradigm by targeting more routine, high-volume procedures that strain provider bandwidth and expose systemic inefficiencies. At LSI USA ’25, a panel of operator-led companies took the stage to discuss how their technologies are addressing two of the biggest challenges in healthcare: provider scarcity and rising costs. While traditional robotics may have focused on elite surgical tasks, the next wave is all about scalable, task-specific solutions that work within real-world clinical and economic constraints. From Specialized to Scalable: Redefining the Role of Medical Robotics Rather than targeting a handful of high-reimbursement procedures, these companies are applying robotics to common clinical workflows —  vascular access , phlebotomy, biopsies — that collectively accoun...